by Sermonix Pharmaceuticals | Dec 3, 2020 | News
The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 02, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
by Sermonix Pharmaceuticals | Oct 13, 2020 | News
Working with Tempus to identify and enroll trial participants, study will evaluate safety of combination for treatment of women with ER+/HER2- metastatic breast cancer and an ESR1 mutation COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals...
by Sermonix Pharmaceuticals | Sep 30, 2020 | News
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include seven precision-medicine Exactis Network study locations COLUMBUS, Ohio, Sept. 30, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
by Sermonix Pharmaceuticals | Jul 9, 2020 | News
The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
by Sermonix Pharmaceuticals | Jun 18, 2020 | News
University of Chicago preclinical study compared combination to that of fulvestrant and palbociclib in a mouse intraductal model with cells carrying Y537S ESR1 mutations. Findings will be shared June 22 as part of AACR’s Clinical Endocrinology 2 session. COLUMBUS,...
Recent Comments